Vivani Medical Secures $10 Million Financing and Advances NPM-139 Development

Vivani Medical Milestones and Update on Business Strategies, Released Financial Reports and Announced Equity Financing

Business Updates

Vivani Medical Inc., a leading biopharmaceutical company, updated its business plans. Vivani signed a share purchase agreement on 11 August 2025, to issue and sell an approximate of 7,936,507 shares of common stock, at $1.26 per share. The closing market price on the same date was announced in a private placement among two investors, consisting of an entity beneficially owned by Gregg Williams. The private sale transaction is predicted to result in gross proceeds of an estimated $10.0 million, which secures Vivani’s financial status into the second half of 2026 and contributes to specifying and leveraging the development of NPM-139 into the clinical stage.

Vivani introduced the advancement of NPM-139 on 8th August 2025, a semaglutide implant for empowering weight loss data. The company also hired Anthony Baldor for the chief financial officer position. With his 20+ years of financial management experience in the biotechnology sector, from 11th June 2025, he contributed excellence to the company. Further, on 12th May 2025, Vivani signed a securities purchase agreement to sell and issue an estimated 2,912,621 shares, each one for $1.03 per share, that is predicted to result in gross proceeds of around $3.0 million in a private placement. On 15th April 2025, Okava and Vivani Pharmaceuticals expanded their 2019 partnership, primarily focused on cats and now also for dogs, in the development of OKV-119.

The upcoming expected milestones are focusing on planning the clinical development of NPM-139 by 2026. Vivani is also behind completing the spin-off of Cortigent Inc., a brain implant device development company. Also, the company might enable the NPM-139 program updates this year. It will consist of the proposed design of the NPM-139 clinical program via a dose calculating weight maintenance study’s outcome.

Financial Reports

On 30th June 2025, the company had cash and cash equivalents and prohibited cash of $8.1 million, in comparison to $19.7 million on 31st December 2024. The $11.6 million was a decreased amount carrying long-term loss of $13.4 million, separately offset by a $1.1 million net change to operations of assets and liabilities. Including non-cash items of $1.1 million for amortization and depreciation of equipment and property, lease expenses, and stock-related compensation. The R&D expenses throughout the three months ended June 30, 2025, were $4.8 million. The G&A expenses in the three months ended June 30, 2025, were $2.7 million.